Last reviewed · How we verify
tremelimumab (treme)
Tremelimumab is a monoclonal antibody that blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.
Tremelimumab is a monoclonal antibody that blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses. Used for Unresectable hepatocellular carcinoma (in combination with durvalumab), Mesothelioma (in combination with durvalumab).
At a glance
| Generic name | tremelimumab (treme) |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | CTLA-4 inhibitor |
| Target | CTLA-4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
CTLA-4 is an immune checkpoint protein that suppresses T cell activation. By binding to CTLA-4, tremelimumab prevents its interaction with B7 ligands on antigen-presenting cells, thereby releasing the brake on T cell proliferation and activation. This allows the immune system to mount a stronger attack against cancer cells.
Approved indications
- Unresectable hepatocellular carcinoma (in combination with durvalumab)
- Mesothelioma (in combination with durvalumab)
Common side effects
- Immune-related colitis
- Immune-related hepatitis
- Immune-related pneumonitis
- Fatigue
- Rash
- Diarrhea
Key clinical trials
- Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC (PHASE2)
- Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck (PHASE1, PHASE2)
- Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer (PHASE2)
- Pulmonary sarcomatoid_MEDI4736+Treme (PHASE2)
- Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer (PHASE1, PHASE2)
- Study of Tremelimumab in Patients With Advanced Solid Tumors (PHASE2)
- Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC (PHASE2)
- A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tremelimumab (treme) CI brief — competitive landscape report
- tremelimumab (treme) updates RSS · CI watch RSS
- AstraZeneca portfolio CI